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The objective of this study was to investigate the efficacy of first-line chemotherapy containing irinotecan and/or oxaliplatin in patients
with advanced mucinous colorectal cancer. Prognostic factors associated with response rate and survival were identified using
univariate and multivariate logistic and/or Cox proportional hazards analyses. The population included 255 patients, of whom
49 (19%) had mucinous and 206 (81%) had non-mucinous colorectal cancer. The overall response rates for mucinous and
non-mucinous tumours were 18.4 (95% CI, 7.5–29.2%) and 49% (95% CI, 42.2–55.8%), respectively (P¼0.0002). After a median
follow-up of 45 months, median overall survival for the mucinous patients was 14.0 months compared with 23.4 months for the non-
mucinous group (hazard ratio (HR), 1.74; CI 95%, 1.27–3.31; P¼0.0034). After adjustment for significant features by multivariate
Cox regression analysis, mucinous histology was associated with poor overall survival (HR, 1.593, 95% CI, 1.05–2.40; P¼0.0267),
together with performance status ECOG 2, number of metastatic sites X2, and peritoneal metastases. This retrospective analysis
shows that patients with mucinous colorectal cancer have poor responsiveness to oxaliplatin/irinotecan-based first-line combination
chemotherapy and an unfavourable prognosis compared with non-mucinous colorectal cancer patients.
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Colorectal cancers are derived from the cells of the colonic
epithelium, and they are mainly constituted by non-mucinous
cancers. However, mucinous carcinomas make up 10–20% of all
colorectal cancers (Symonds and Vickery, 1976; Minsky et al, 1987;
Green et al, 1993), with different clinicopathological character-
istics, distinct genetic profiles, and histogenic pathways (Parham,
1923; Hanski, 1995; Zhang et al, 1999; Kim et al, 2005; Song et al,
2005). It has also been hypothesised that a mucinous pathway of
carcinogenesis leads to a mucinous phenotype (Hanski, 1995).
Mucinous adenocarcinoma is characterised by abundant extra-
cellular mucin produced by tumour cells. By definition, a 50% or
greater mucinous component is required for the designation of
mucinous colorectal carcinoma (Hamilton and Aaltonen, 2000).
This subtype of tumour is to be differentiated from signet ring cell
carcinoma that is constituted by single tumour cells with
intracytoplasmic mucin displacing their nuclei aside with 50% or
more of such components. The prognostic significance of
mucinous carcinoma is controversial. In some studies, mucinous
histology has been shown to be an independent negative
prognostic factor (Connelly et al, 1991; Green et al, 1993; Secco
et al, 1994), but not in others (Minsky et al, 1987; Green et al, 1993;
Enriquez et al, 1998; Consorti et al, 2000). Both the American Joint
Committee on Cancer and the College of American Pathologists
consider that the mucinous subtype has not been proven as a
statistically significant prognostic factor independent of histologi-
cal grade (Compton et al, 2000a, 2000b).
For the treatment of advanced colorectal cancer, after decades in
which 5-fluorouracil (5-FU) was the only drug approved,
irinotecan (IRI) and oxaliplatin (OXA) have been added during
the last decade to the armamentarium of agents with activity in
colorectal cancer, setting a new benchmark of survival for patients
with unresectable advanced colorectal at around 20 months
(Grothey et al, 2004; Goldberg et al, 2007). Interestingly, with the
more recent incorporation of biological therapies, such as
bevacizumab and cetuximab, overall survival (OS) of advanced
colorectal cancer patients has been further improved. Now, various
treatment options combining cytotoxic and targeted therapies are
currently available for these patients (Grothey and Marshall, 2007).
The effect of mucinous histology on advanced colorectal cancer
patients treated with first-line chemotherapy has been only
recently examined by Negri et al (2005). In this report, 45 patients
with advanced mucinous colorectal cancer have been shown to
have a poorer response to 5-FU-based first-line chemotherapy and
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sto have reduced survival compared with 90 patients with non-
mucinous colorectal cancer. The overall response rate and median
survival for mucinous colorectal cancer were 22% and 11.8 months
compared with 47% (P¼0.0058) and 17.9 months (P¼0.0372) for
non-mucinous tumours (Negri et al, 2005). No data were available
on the effect of mucinous histology over the treatment efficacy
of first-line regimens containing IRI and OXA. The aim of
this analysis was to investigate the response rate and the OS
of fluoropyrimidines in combination with IRI and/or OXA as
first-line chemotherapy in patients with mucinous colorectal
carcinoma.
PATIENTS AND METHODS
The population consisted of 255 consecutive unselected patients
who had undergone first-line chemotherapy for colorectal cancer
at five oncology departments between September 2001 and
December 2006. All patients had histologically confirmed diag-
nosis of colorectal adenocarcinoma, unidimensionally measurable
disease, first-line chemotherapy containing fluoropyrimidines plus
IRI and/or OXA, adjuvant/neoadjuvant treatment completed more
than 6 months earlier, adequate hematological/clotting, hepatic,
renal, and cardiac functions. Moreover, patients were excluded if
they had received prior chemotherapy for metastatic colorectal
cancer, had previous malignancy within 5 years (except for basal
cell skin cancer or in situ carcinoma of the cervix), and were from
families with familial adenomatous polyposis or hereditary non-
polyposis colorectal with a highly penetrant genetic predisposition
to colorectal cancer.
The pathologists from the five referral hospitals were asked to
review tumour specimens and assessed the tumour type. To avoid
evaluator variability in the patients, all the pathologists were not
aware of the clinical results. By definition, tumours with mucinous
histology had mucin constituting more than 50% of tumour
volume. The colorectal adenocarcinomas without any mucinous or
o50% of the mucinous component were designated as non-
mucinous carcinoma (Hamilton and Aaltonen, 2000). Tumours
with signet ring cells component and undifferentiated carcinoma
were excluded from the analysis.
The following data were collected from the hospital records for
each patient: sex, age, performance status (PS) evaluated according
to the Eastern Cooperative Oncology Group (ECOG) criteria,
primary tumour location, histology, earlier resection of the
primary tumour, earlier tumour location, adjuvant therapy
(chemotherapy and/or radiotherapy); baseline haemoglobin,
CEA, and CA19-9 levels; number and sites of metastatic disease;
regimen used as first-line treatment (containing fluoropyrimidines
plus IRI, OXA, or both), and objective response to treatment.
Patients receiving fluoropyrimidines alone or biologic agents
(bevacizumab and cetuximab) as first-line chemotherapy were
excluded from the analysis. Laboratory variables were initially
recorded as continuous variables and later dichotomised according
to the normal upper limit. Primary tumours were assigned to one
of the two anatomical sites: right-sided colon (arising in the
caecum, ascending colon, hepatic flexure, and transverse colon);
left-sided colon (arising in the descending colon, sigmoid colon,
rectosigmoid junction, and rectum).
Treatment protocols and evaluation of response
The following first-line regimens were used to treat this popula-
tion: (i) FOLFOX: OXA 85mgm
 2 day 1, leucovorin 200mgm
 2
day 1–2, bolus 5-FU 400mgm
 2 day 1–2, 22h continuous infu-
sion 5-FU 600mgm
 2 day 1–2, every 2 weeks; (ii) XELOX: cape-
citabine 1000mgm
 2 b.i.d. day 1–14, OXA 100–130mgm
 2 day 1,
every 3 weeks; (iii) FOLFIRI: IRI 180mgm
 2 day 1, leucovorin
200mgm
 2 day 1–2, bolus 5-FU 400mgm
 2 day 1–2, 22h
continuous infusion 5-FU 600mgm
 2 day 1–2, every 2 weeks; (i.v.)
XELIRI: capecitabine 1,000mgm
 2 b.i.d. day 1–14, IRI 250mgm
 2
i.v. day 1, every 3 weeks; (v) FOLFOXIRI: IRI 165mgm
 2 followed
by OXA 85mgm
 2 leucovorin 200mgm
 2, and 5-FU 3200mgm
 2
administered as a 48-h flat continuous infusion, every 2 weeks.
Response evaluation criteria in solid tumour (RECIST) guide-
lines were used to define all responses (Therasse et al, 2000). All
radiology studies were reviewed for confirming the treatment
outcomes.
Statistical analysis
The two groups of patients were compared using 2 2 tables for
binary factors using the w
2-test, or the Fisher’s exact test where
appropriate. OS was calculated from the starting date of first-line
chemotherapy until death of any cause, or censored at last follow-
up visit. Time-to-progression (TTP) was calculated from the
starting date of first-line chemotherapy to the date of progression
(per investigator assessment), or death from any cause. Survival
data were analysed using the Kaplan–Meier product-limit method.
Comparison of survival curves was carried out using the log-rank
test. The first part of the analysis consisted of the univariate
comparison of survival functions for factors that could potentially
affect the survival time using the log-rank test. Then, we performed
a multivariate analysis using stepwise Cox proportional hazards
regression modelling. P-values o0.05 were considered statistically
significant, and all P-values correspond to two-sided significance
tests. Approval of the study was obtained from local research and
ethics committees.
RESULTS
The characteristics of 255 patients are presented in Table 1. Forty-
nine patients (19%) had a histologically confirmed diagnosis of
mucinous colorectal cancer. There were 153 male and 102 female
patients, with a median age of 67 years (range, 43–89). Mucinous
tumours were more frequently located into the right colon (55%
compared with 29%, respectively; P¼0.002). More patients in the
mucinous group had X2 metastatic sites compared with non-
mucinous patients (47 and 33%, respectively; P¼0.096). Liver,
peritoneum, and lymph nodes were the most common metastatic
sites in patients with mucinous cancers, whereas liver, lungs, and
peritoneum were most common in patients with non-mucinous
cancers. The peritoneum was more commonly noted in patients
with mucinous colorectal cancer (39% compared with 12% of
patients with non-mucinous tumours; Po0.001), whereas liver and
lung metastases were found in 76 and 28% of the non-mucinous
group compared with 53 and 12% of the mucinous group,
respectively (P¼0.002 and P¼0.034, respectively). Only two
patients had unresectable locally advanced disease.
Chemotherapy regimens
Details of first-line regimens used for each patient are shown in
Table 1. In all, 66% of patients were treated with OXA-based
regimens, 26% of patients with IRI-based regimens, and 8% of
patients with OXA/IRI-based chemotherapy. There was no signi-
ficant difference between mucinous and non-mucinous groups in
terms of treatment regimens. Moreover, no significant difference in
the mean number of administered courses of first-line chemother-
apy between mucinous and non-mucinous tumours (8 and 10
cycles, respectively) was encountered. A total of 143 (69%) patients
with non-mucinous tumour (IRI-based¼94 patients; OXA-base-
d¼33 patients; IRI/OXA-based¼7 patients; and ¼9 patients) and
31 (63%) patients with mucinous tumours (IRI-based¼22 patients;
OXA-based¼5 patients; IRI/OXA-based¼2 patients; and other¼2
patients) received second-line chemotherapy.
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sTreatment response
All the patients had measurable disease and were evaluated
for response (Table 2A and B). Ten patients discontinued the
treatment prematurately because of early disease progression,
seven (3%) patients with non-mucinous, and three (6%) with
mucinous cancer (P¼NS). Fourteen patients achieved complete
response and 96 patients achieved partial remission,; thus, the
overall response rate was 43.1% (95% CI, 37.1–49.2). In the
mucinous colorectal cancer group, nine patients reported a partial
response for an overall response rate of 18.4% (95% CI,
7.5–29.2%). In the non-mucinous group, 14 patients achieved
complete response and 87 achieved partial remission for an overall
response rate of 49.0% (95% CI, 42.2–55.8%). The difference of
response rate between the two groups was statistically significant
(P¼0.0002). On multivariate analysis (Table 3), patients with PS
0–1 (risk ratio, 6.06; 95% CI, 1.32–27.7; P¼0.02), non-mucinous
histology (risk ratio, 3.41; 95% CI, 1.53–7.61; P¼0.002), and
without peritoneal metastases (risk ratio, 2.70; 95% CI, 1.14–6.37;
P¼0.026) had a significantly increased probability of tumour
response to chemotherapy.
Survival
After a median follow-up of 45 months, the median TTP for
mucinous colorectal cancer patients was 4.1 months compared
with 8.6 months for the non-mucinous group (P¼0.0039)
(Figure 1). The HR for risk of progression for patients with
mucinous colorectal cancer compared with non-mucinous
tumours was 1.57 (95% CI, 1.21–2.74). The median OS for the
mucinous colorectal cancer patients was 14.0 months compared
with 23.4 months in the non-mucinous colorectal cancer group
(HR¼1.74; 95% CI, 1.27–3.31; P¼0.0034; Figure 2). The 1-year
OS was 53.1% (95% CI, 45.5–60.7%) for the mucinous group
compared with 77.4% (95% CI, 74.4–80.4%) for the non-mucinous
group.
The univariate analysis (Table 4) showed the other four
variables to be significantly associated with poor survival: PS
ECOG 2, number of metastatic sites X2, peritoneal metastasis, and
haemoglobin p12gl
 1. Two variables, CEA and CA19-9, had
missing data, and they were not included in the multivariate
analysis. After correcting for significant prognostic factors by
multivariate Cox regression analysis, mucinous histology was
Table 1 Patient characteristics
Characteristic Non-mucinous (n¼206) Mucinous (n¼49) P-value Overall (n¼255)
Sex
Male 122 (59%) 31 (63%) 0.721 153 (60%)
Female 84 (41%) 18 (37%) 102 (40%)
Median age, years (range) 67 (43–84) 67 (45–89) 0.927 67 (43–89)
Peformance status (ECOG)
0 102 (50%) 21 (43%) 0.263 123 (48%)
1 91 (44%) 22 (45%) 113 (44%)
2 13 (6%) 6 (12%) 19 (8%)
Primary tumour site
Right-sided 61 (29%) 27 (55%) 0.002 88 (34%)
Left-sided 144 (70%) 22 (45%) 16 (65%)
Synchronous primaries 1 (1%) 0 (0%) 1 (1%)
Grading
1 22 (11%) 3 (6%) 0.583 25 (10%)
2 121 (59%) 26 (53%) 147 (57%)
3 52 (25%) 14 (29%) 66 (26%)
Missing 11 (5%) 6 (12%) 17 (7%)
Resection of primary tumour 144 (70%) 31 (63%) 0.466 175 (69%)
Earlier adjuvant chemotherapy 74 (36%) 19 (39%) 0.835 93 (36%)
Number of metastatic sites
0–1 138 (67%) 26 (53%) 0.096 164 (64%)
X2 68 (33%) 23 (47%) 91 (36%)
Site of metastatic disease
Liver 157 (76%) 26 (53%) 0.002 183 (72%)
Peritoneum 24 (12%) 19 (39%) o0.001 43 (17%)
Lymph node 18 (9%) 8 (16%) 0.188 26 (10%)
Lung 58 (28%) 6 (12%) 0.034 64 (25%)
CNS 4 (2%) 0 (%) 4 (2%)
Bone 3 (1%) 1 (2%) 4 (2%)
Other 20 (10%) 15 (30%) 35 (14%)
Haemoglobin level, gl
 1 12.9 (8.2–17.4) 12.2 (8.2–16.1) 0.077 12.7 (8.2–17.4)
CEA, ngml
 1 18.4 (0–1084) 14.4 (0.9–1151) 0.851 17.0 (0–1151)
CA19-9, Uml
 1 456 (0–20000) 122 (3.2–48000) 0.928 45.0 (0–48000)
First-line regimen
IRI-based regimen 56 (27%) 9 (18%) 0.730 65 (26%)
OXA-based regimen 135 (66%) 34 (70%) 0.275 169 (66%)
IRI/OXA-based regimen 15 (7%) 6 (12%) 21 (8%)
CEA¼carcinoembryonic antigen; CNS¼central nervous system; ECOG¼Eastern Cooperative Oncology Group; IRI¼irinotecan; OXA¼oxaliplatin.
First-line chemotherapy in mucinous colorectal cancer
V Catalano et al
883
British Journal of Cancer (2009) 100(6), 881–887 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sconfirmed as poor prognostic factor (HR, 1.593; 95% CI, 1.05–
2.40; P¼0.0267; Table 5). Multivariate regression analysis (Table 5)
also found PS ECOG 2, number of metastatic sites X2, and
peritoneal metastases to be negative independent prognostic
factors.
DISCUSSION
It is generally recognised that mucinous tumours of the colon and
rectum have a worse prognosis than non-mucinous tumours
(Umpleby et al, 1985; Green et al, 1993; Consorti et al, 2000), and
they occur more frequently in the proximal colon (Umpleby et al,
1985; Green et al, 1993; Sarli et al, 2008), metastasise with high
frequency to lymph nodes and to the peritoneum (Umpleby et al,
1985; Minsky et al, 1987), are more prone to local recurrence
(Umpleby et al, 1985), and are typically diagnosed at an advanced
stage (Green et al, 1993; Younes et al, 1993).
Published literature presents conflicting results on the associa-
tion between worse prognosis and mucinous histology of colo-
rectal cancer. However, the interpretation of results may be
arduous for many reasons. Data are mostly derived from series
that assessed the prognosis of patients treated with curative
surgery alone, at different stages of disease, and did not evaluate
closely a role for chemotherapy in this subset of patients (Green
et al, 1993; Younes et al, 1993; Consorti et al, 2000; Kanemitsu
et al, 2003). Moreover, the geographical variations in the
epidemiology of mucinous colorectal cancer may likely account
for the conflicting results (Sarli et al, 2008).
Our analysis showed a highly statistically significant poor
survival for patients with mucinous tumours compared those with
non-mucinous tumours (14 months vs 23.4 months, respectively).
All the patients included in the present analysis had advanced
colorectal cancer and were treated with first-line chemotherapy
containing IRI and/or OXA in addition to fluoropyrimidines,
considered as standard drugs for this disease at that time.
Characteristics of patients were well balanced according to the
different clinicopathological variables, except for a higher propor-
tion of patients with mucinous colorectal cancer who had
peritoneal metastases and were right-sided. Conversely, more
patients with non-mucinous tumours had liver and lung metas-
tases. These findings were also found in earlier studies (Umpleby
et al, 1985; Minsky et al, 1987; Negri et al, 2005), and, to our
opinion, these imbalances cannot justify the poor prognosis of
patients with mucinous carcinomas. Moreover, the multivariate
analysis confirmed the independent poor prognostic role of
mucinous histology (HR 1.593, 95% CI 1.05–2.40; P¼0.0267),
together with PS, number of metastatic sites, and peritoneal
metastasis.
In advanced colorectal cancer, the less responsiveness to first-
line chemotherapy of mucinous tumours compared with non-
mucinous tumours has been only recently reported in a
case–control study by the group of the Royal Marsden Hospital
Table 2 Response rate according to histology (A) and regimen of
first-line chemotherapy (B)
(2A)
Response
Mucinous
(n¼49)
Non-mucinous
(n¼206)
Complete response 0 14 (6.8%)
Partial response 9 (18.4%) 87 (42.2%)
Overall response rate, % (95% CI) 18.4 (7.5–29.2) 49.0 (42.2–55.8)
Stable disease 18 (36.7%) 57 (27.7%)
Progressive disease 22 (44.9%) 48 (23.3%)
(2B)
Chemotherapy
regimen
N Mucinous
responders
a
Non-mucinous
responders
a
OXA-based 169 6/34 (17.6%) 57/135 (42.2%)
IRI-based 65 1/9 (11.1%) 32/56 (57.1%)
OXA/IRI-based 21 2/6 (33.3%) 12/15 (80.0%)
CI¼confidence interval; IRI¼iriotecan; OXA¼oxaliplatin.
aResponders¼complete
plus partial responses according to the RECIST.
Table 3 Multivariate logistic regression model for tumour response to
1st line chemotherapy (n¼255)
Variable Risk ratio (95% CI) P-value
Performance status (ECOG)
0–1 6.06 (1.32–27.7) 0.020
Histology
Nonmucinous 3.41 (1.53–7.61) 0.002
No peritoneal metastases 2.70 (1.14–6.37) 0.026
ECOG¼Eastern Cooperative Oncology Group; CI¼confidence interval.
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Figure 1 Time-to-progression for patients with mucinous and non-
mucinous colorectal cancer (n¼255).
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Figure 2 Overall survival for patients with mucinous and non-mucinous
colorectal cancer (n¼255).
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s(Negri et al, 2005). Our aim was to confirm the same results in a
similar subset of patients, but receiving IRI and OXA in addition to
fluoropyrimidines as first-line chemotherapy. Mucinous colorectal
cancers had a response rate to IRI and/or OXA-based chemo-
therapy of 18.4% compared with 49% for non-mucinous tumours
(P¼0.0002). Logistic regression analysis revealed that histology,
namely, mucinous, together with bad PS, and peritoneal metastasis
were independent predictive factors for poor response.
The mechanisms that lead to this significant difference in IRI,
OXA, and fluoropyrimidine sensitivity of mucinous tumours
compared with non-mucinous tumours are unknown. Mucinous
tumours have been characterised by a number of genetic and
biological features, which may explain in part the different beha-
viour compared with that of non-mucinous tumours. Mucinous
colorectal carcinomas have higher incidence of high degree of
microsatellite instability (MSI-H) (Kakar et al, 2004; Song et al,
2005; Ogino et al, 2006; Tanaka et al, 2006; Sarli et al, 2008), K-ras
mutation (Zhang et al, 1999; Bazan et al, 2002; Ogino et al, 2006),
BRAF mutation (Song et al, 2005; Li et al, 2006; Ogino et al, 2006;
Tanaka et al, 2006), and less expression of p53 (Zhang et al, 1999;
Ogino et al, 2006) than do non-mucinous colorectal cancer. Given
the unclear significance and heterogeneity of mucinous colorectal
cancers, it seems difficult to find possible explanations for the
relatively chemoresistance of such tumours. It is recognised that
defective DNA mismatch repair (MMR) leads to MSI and results in
resistance to many antineoplastic drugs, such as antimetabolites,
alkylating, and platinum agents, and inhibitors of topoisomerases.
There are some evidences in vitro that suggest a correlation
between response to 5-FU, OXA, and IRI and MSI (Magrini et al,
2002; Arnold et al, 2003; Warusavitarne and Schnitzler, 2007). Our
analysis plan did not include an MSI analysis. First, we focused on
the clinical role of mucinous histology without performing
molecular analysis, as the simple knowledge on the histopatholo-
gical mucinous feature may be per se a relevant information.
Second, two recently published studies (Braun et al, 2008; Mu ¨ller
et al, 2008) have shown low MSI in colorectal carcinomas (about
4%), and no significant association with treatment (OXA- and
IRI-based) outcomes in terms of response rate and OS; therefore,
the use of this marker may be of limited value. The discrepancy
between such a low percentage of MSI and the higher percentage of
MSI reported in earlier studies might be the result of many
reasons, such as a variable definition of MSI-H, the use of different
markers, or a consequence of the selection of patients (Popat et al,
2005; Mu ¨ller et al, 2008).
Recently, Glasgow et al (2005) analysed some molecular markers
for response to chemotherapy in mucinous and non-mucinous
Dukes C colorectal cancer. The authors found an overexpression of
TS and GSTP1 (glutathione S-transferase pi) genes in mucinous
tumours. As GSTP1 is a major rout of detoxification of platinum
agents, one could expect that the overexpression of TS and GSTP1
genes in mucinous tumours may be responsible for decreased
clinical response to treatment with 5-FU and OXA.
Several markers, oncogenes and suppressor genes, multidrug-
resistance-related proteins, and genomic polymorphisms that
influence DNA metabolism, DNA damage, programmed cell death,
and angiogenesis may be responsible of colorectal cancer patient’s
variation in response to chemotherapy. It is important to stress
Table 4 Factors associated with overall survival in the univariate analysis
Variable n MST (months) 1-year-survival (%) P-value
Sex
Male 153 21.2 74.3
Female 102 22.6 70.9 0.4040
Age
p65 years 111 21.7 76.9
465 years 144 21.5 69.8 0.0828
Performance status (ECOG)
0–1 236 23.0 76.9
2 19 6.2 22.6 o0.0001
Primary tumor site
Right-sided 88 21.0 75.6
Left-sided 166 21.5 71.6 0.5222
Histology
Nonmucinous 206 23.4 77.4
Mucinous 49 14.0 53.1 0.0034
Previous adjuvant treatment
Yes 93 27 75,3
No 162 20,7 71,6 0.0619
Number of metastatic sites
0–1 164 25.2 80.0
X2 91 14.2 59.9 0.0003
Liver metastasis
Yes 183 21.8 75.6
No 72 20.5 66.4 0.3537
Peritoneal metastasis
Yes 43 11.3 47.9
No 212 23.7 78.0 o0.0001
Nodal metastasis
Yes 26 14.6 61.7
No 229 22.6 74.1 0.0581
Lung metastasis
Yes 64 26.0 83.6
No 191 20.6 69.5 0.190
Haemoglobin level
p12gl
 1 90 18.0 61.2
412gl
 1 165 22.4 79.0 0.0489
CEA
p5ngml
 1 79 24.0 79.8
45ngml
 1 153 20.8 69.7 0.0214
CA19-9
p30Uml
 1 117 26.3 80.9
430Uml
 1 114 17.2 65.2 0.0004
ECOG¼Eastern Cooperative Oncology Group; CEA¼carcinoembryonic antigen;
MST¼median survival time.
Table 5 Factors associated with a poor overall survival in mutivariate
analysis (n¼255)
Variable Hazard ratio (95% CI) P-value
Performance status (ECOG)
2 3.526 (2.07–5.99) o0.0001
Histology
Mucinous 1.593 (1.05–2.40) 0.0267
Number of metastatic sites
X2 1.472 (1.04–2.08) 0.0300
Peritoneal metastasis
Yes 1.588 (1.01–2.49) 0.0461
Haemoglobin level
p12gl
 1 1.123 (0.81–1.55) 0.4870
ECOG¼Eastern Cooperative Oncology Group; CI¼confidence interval.
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sthat before clinical application, any biomarker need to be
independently validated. Moreover, for mucinous carcinomas,
many of the above reported biomarkers may differently be
expressed in each tumour, and this could make very difficult to
potentially predict response to chemotherapy for this hetero-
geneous tumours.
Another key point of discussion is the integration of conven-
tional cytotoxic agents with novel biologic agents. Targeted agents
enhance the efficacy of conventional cytotoxic agents (Goldberg
et al, 2007). We actually lack data investigating the outcome of
patients with mucinous colorectal cancer treated with novel agents
and traditional drugs (fluoropyrimidines, IRI, and OXA).
Despite the possible limitations of this retrospective analysis, the
observations of this study are consistent with those of the group of
the Royal Marsden Hospital (Negri et al, 2005), which showed that
mucinous advanced colorectal cancer patients treated with first-
line fluoropyirimidine-based chemotherapy have similar response
rate and OS. However, these retrospective analyses were based on a
rather small number of patients. It would be very worthwhile to try
to confirm these findings in an analysis of large, prospective,
randomised trials, such as N9741, NO16966, and so on. The
informations derived on mucinous histology may help researchers
and practitioners in designing future studies (e.g., stratification of
patients according to the mucinous histology) and in making
clinical decisions that will improve the outcome of patients with
such histological type. Trying to identify subsets of patients who
are likely to derive more benefit from a particular treatment not
only helps to derive greater efficacy, but also spares many patients
from unnecessary toxicity.
In conclusion, this retrospective analysis on advanced colorectal
cancer showed poor responsiveness and prognosis for patients
with mucinous colorectal cancer treated with first-line chemother-
apy containing 5-FU, IRI, and OXA. Further investigations should
be carried out to better characterise the genetic profile and the
pharmacological markers, which could explain the unfavourable
responsiveness and prognosis of mucinous colorectal tumours.
Assessment of clinical outcome of mucinous colorectal cancer
treated with cytotoxic drugs and novel agents is highly warranted.
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